Genentech buys Amphora's oncology program
Genentech buys Amphora's oncology program
Genentech gains access to all of the intellectual property of Amphora's entire program for an unnamed oncology target with potential for treating multiple cancer indications. The program includes a lead candidate in preclinical development and several backup series.
Further details of the deal were not disclosed.
"We are delighted that Genentech sees the potential value of one of our early stage programs," said C. Nicholas Hodge, Amphora's chief science officer and founder.
"I personally see this as validation of our ability to produce high quality drug candidates," Hodge added.
Boutique executive search services with best in class global network, contacts and market mastery.
Deeply connected and engaged personal service approach, long-term investment in client community and 25 year history of strong relations with both Multi-National leaders and Private Equity partners.